Physician profile

Juddi Yeh

Hematology & Oncology · College Station, TX

NPI 1427271154

$469.38

in general payments reported to CMS, 2019-2025

7 companies · none reported in 2025

See the full distribution for Hematology & Oncology

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$213.31
Education$20.00

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Tempus Ai, INC $148.09 2024 Xt Cdx
Janssen Biotech, INC. $130.01 2019-2024 Tecvayli, Darzalex, Imbruvica
Myriad Genetic Laboratories, INC. $124.21 2022
Tactile Systems Technology INC $20.16 2023 Entre Plus, Flexitouch Plus
Aveo Pharmaceuticals, INC. $20.00 2024
Clovis Oncology, INC. $14.40 2019
Astrazeneca Pharmaceuticals LP $12.51 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Juddi Yeh

$469.38

in general payments reported 2019-2025

Years
2019-2024
Top company
Tempus Ai, INC

https://glasscript.com/doctor/291403/juddi-yeh

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.